Q2 2022 Eris Lifesciences Ltd Earnings Call Transcript
Thank you. Am I audible?
Yes, sir.
Great. Good afternoon, everyone, and welcome to our second quarter conference call. I'm Krishnakumar, and I'm happy to share the highlights of the quarter with you. As per the AIOCD retail audit, Indian pharma market grew at 15% in quarter 2 of this year, but this was on a low base of 1% growth in quarter 2 of last year. The 15% growth in quarter 2 was once again led by acute therapies, which enjoyed the benefit of a low base effect from last year, along with the surge of infections like H1N1, Dengue and Chikungunya after the wave 2 of COVID subsided.
I'm happy to share that Eris grew at 11.4% in quarter 2 of this year on top of a 7.4% growth in quarter 2 of last year. We have also been looking at how our business has performed from pre-COVID levels. The Indian pharma market, from its pre-COVID level, has grown at a CAGR
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
